Natural products modulate non-apoptotic cell death to bypass apoptotic blockades in cancerNatural products may help cancer cells bypass treatment resistance

Acquired multidrug resistance (MDR) and apoptosis evasion severely limit the efficacy of conventional cancer therapies. Triggering non-apoptotic regulated cell death (RCD)—specifically ferroptosis, pyroptosis, cuproptosis, and disulfidptosis—offers a promising therapeutic paradigm to bypass these apoptotic blockades. Natural products (NPs) have emerged as potent modulators of these alternative RCD pathways owing to their unique structural diversity and multi-target network pharmacology. This review systematically delineates the molecular mechanisms by which phytochemicals disrupt cellular redox homeostasis and exploit metabolic vulnerabilities to execute non-apoptotic cytolysis. Furthermore, we highlight how NP-induced RCD triggers immunogenic cell death (ICD) and remodels the immunosuppressive microenvironment, thereby establishing a reciprocal reinforcement loop with host antitumor immunity. Despite compelling preclinical evidence, the clinical translation of NPs is hampered by pharmacokinetic limitations, target ambiguity, and adaptive resistance. To address these translational bottlenecks, we discuss the integration of smart nano-co-delivery platforms, artificial intelligence (AI)-driven structural optimization, and PROTAC technology. Ultimately, we emphasize the critical necessity of transitioning toward precision oncology frameworks through biomarker-guided patient stratification and pathway-specific pharmacodynamic monitoring, providing a comprehensive roadmap for leveraging NPs to combat recalcitrant malignancies.